Intermittent Claudication Clinical Trial
Official title:
Cross-sectoral Rehabilitation for Patients With Intermittent Claudication: Effects and Patient Experience - The CIPIC-Rehab Study (Cross-sectoral Intervention for Patients With Intermittent Claudication)
Exercise training combined with other lifestyle changes are essential elements in
conservative management of patients with Intermittent Claudication (IC). IC is essentially
caused by atherosclerosis, which reduces blood flow to the legs and leads to cramping leg
pain when walking. Patients suffering from IC may have difficulty in exercising and changing
lifestyle without systematic intervention despite the risk of morbidity, mortality and
hospitalization. Today, rehabilitation programs, including supervised exercise, exist for
patients suffering ischemic heart disease but not for patients with IC, despite evidence that
exercise therapy is highly beneficial for patients suffering IC.
The overall aim of the present study is to examine the effect of conservative management of
patients with IC provided as a three month, cross-sectoral exercise and lifestyle
intervention program based on the already established cardiac rehabilitation program. Outcome
will be assessed on walking distance and secondly on lifestyle changes and patient reported
outcomes.
Implications:
The project will provide evidence for the effect of cross-sectoral collaborative conservative
management of patients with IC, using the existing rehabilitation program already offered to
patients suffering ischemic heart disease. Moreover, it will elicit knowledge on patient
perceptions of conservative management of IC provided as a proactive cross-sectoral
intervention and ways to support patients with IC in adhering to conservative management.
Main study:
Randomized Clinical Trial comparing Cross-sectoral Training Intervention for Patients with
Intermittent Claudication with standard care.
Patients will be randomized to the intervention or control group using a computer-generated
block randomized allocation scheme.
Sample size:
The expected average base line value of maximal walking distance (MWD) has been set to 120 m
and the investigators want to detect a 50% improvement (60 m). There is a wide variance in
MWD in this patient group, and consequently the standard deviation (SD) is set at 100 m. With
a 5% significance level and 80% power, it will thus be necessary to include 88 patients to
detect an improvement of 60 m in MWD in the intervention group at 12-months follow-up,
compared to the control group. Owing to the previously mentioned risk of comorbidities,
combined with an expected loss to follow-up, a drop-out of 25% must be expected, wherefore
the investigators plan is to include 118 patients in total (59 in each group).
Baseline data:
The following data will be collected at inclusion, before randomization:
Demography (age, gender, housing, marital status, socioeconomic status, level of education)
Height and weight will be combined to report body mass index (BMI) in kg/m^2, waist
circumference, blood pressure.
Cardiovascular risk factors, co-morbidity (Charlson Comorbidity Index), current medications,
blood samples (biomarkers, cholesterol, HBa1C), based on consultation measurements.
Lifestyle: Measured by self-reported smoking behavior, daily physical activity: minimum 30
min. walking time daylit or other exercise activity, self-reported Diet Registration and
alcohol consumption.
Quality of life: Measured using the Vascu-Quality of Life questionnaire (VascuQol).
Depression and anxiety measured with the Hospital Anxiety and Depression Scale (HADS).
Assessment of patients' individual competencies for self-management is measured by using The
Patient Activation Measure" (PAM13).
Maximum walking distance (MWD) and pain-free walking distance (PWD) measured using the
standardized Treadmill Walking Test, and Visual Analog Score for pain. Follow-up Treadmill
Walking Test is performed by a research assistant for whom it is blinded if patients are in
intervention or control group.
Control group - standard care. Patients randomized to the control group will initially
receive brief advice regarding exercise therapy (walking), smoking cessation, and preventive
medical treatment with antiplatelet therapy and statin. Written information about medication,
walking exercise, and a logbook for self-reporting of walking behavior is handed out to the
IC patients in the outpatient clinic at the Department of Vascular Surgery, Rigshospitalet.
The intervention group will initially receive individual brief advice regarding exercise
therapy, smoking cessation advice/course offerings, and preventive medication with
antiplatelet therapy and statin in the outpatient clinic at the Department of Vascular
Surgery. Patients will receive written standard information and a pedometer and be asked to
self-report walking behavior in a logbook.
In the municipality the intervention group will participate in Supervised Exercise Training
and education. This entails that patients will actively engage in groups of 8-10 in 24
supervised physical exercise sessions, each lasting one hour with two weekly sessions.
Physiotherapists in the training Centre will supervise participants' training. The exercises
include varied forms of physical exercise.
The physiotherapists will measure 6 minutes walking test and chair- stand- test prior to and
at completion of the intervention and use the results as a part of an individual motivational
interview with each patient after completion of the 24 training sessions. Furthermore,
participants will be advised in group sessions by the principle investigator, in a 2-hour
long session, about the pathophysiology of IC, medications, lifestyle factors, disease
management, quality of life and how to cope with the disease. A clinical dietician will
advise participants in a 2-hour long session about healthy diet and atherosclerosis. In
addition, participants have access to a 2-4 hour long individual consultation with a
dietician. After completion of exercise training, participants are offered personalized
motivational follow-up text messages. Content, frequency and duration of the text messages
are agreed upon individually for the next 8 months and will be reassessed at 3 and 6-months
follow-up.
Sub-study. Qualitative Study. Individual brief interview and questionnaire survey
supplemented with focus group interviews of patients participating in the intervention group
in the randomized clinical study. A protocol for the study will be drawn up in accordance
with the "Consolidated Criteria for Reporting Qualitative Research" (COREQ).
An interview guide will be developed prior to interviewing. The investigators expect to
explore the following tentative issues: Patient experiences of the training and teaching
sessions, factors facilitating or hindering lifestyle changes, how the use of pedometer,
logbook and text messages influenced motivation/adherence, patient satisfaction with the
intervention and suggestions for future rehabilitation programs.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05400395 -
Clinical Trial for GNX80 in Intermittent Claudication
|
Phase 4 | |
Active, not recruiting |
NCT02341716 -
Hospital- and Home-based Supervised Exercise Versus UNsupervised Walk Advice For Patients With InTermittent Claudication
|
N/A | |
Completed |
NCT02041169 -
Lower Extremity Peripheral Arterial Disease and Exercise Ischemia
|
N/A | |
Completed |
NCT00822172 -
Evaluation of Cilostazol in Combination With L-Carnitine
|
Phase 4 | |
Recruiting |
NCT00538408 -
Whole Body Magnetic Resonance Angiography in Ischemic Patients
|
N/A | |
Completed |
NCT00388128 -
Caffeine and Intermittent Claudication
|
Phase 3 | |
Completed |
NCT00618670 -
Home-based vs. Supervised Exercise for People With Claudication
|
N/A | |
Recruiting |
NCT00146666 -
Evaluation of FM220 in Patients With Peripheral Arterial Disease (PAD)
|
Phase 2 | |
Completed |
NCT00134277 -
Trial Comparing Different Medical Devices for Infragenual Dilatation
|
N/A | |
Completed |
NCT01256775 -
Effect of NCX4016 on Walking Distance in Patients With Peripheral Arterial Occlusive Disease (PAOD)
|
Phase 2 | |
Completed |
NCT00029991 -
Extract of Ginkgo Biloba (EGB 761) and Vascular Function
|
Phase 1/Phase 2 | |
Recruiting |
NCT06299956 -
Supervised Exercise-based Rehabilitation for People With Intermittent Claudication in Denmark
|
N/A | |
Not yet recruiting |
NCT05335161 -
A New Heat Therapy Device for Home-based Leg Heating in Patients With Lower-extremity Peripheral Artery Disease
|
Phase 1 | |
Completed |
NCT04390282 -
Secondary Prevention and Application-based Lifestyle Support for Patients With Intermittent Claudication
|
N/A | |
Completed |
NCT03271710 -
Study to Evaluate the Lower Extremity Intervention With Integrated Embolic Protection Using the Vanguard IEP System
|
N/A | |
Completed |
NCT02380794 -
Novel Treatment of Intermittent Claudication in Patients With Peripheral Arterial Disease Using Danshen Gegen (D&G) Capsule
|
Phase 2 | |
Active, not recruiting |
NCT02276937 -
Randomized Phase IIb Trial of DVC1-0101
|
Phase 2 | |
Completed |
NCT02097082 -
Treatment of SFA Lesions With 480 Biomedical STANZA™ Drug-Eluting Resorbable Scaffold (DRS) System
|
N/A | |
Recruiting |
NCT00539266 -
Autologous Bone Marrow-derived Mononuclear Cells for Therapeutic Arteriogenesis in Patients With Limb Ischemia
|
Phase 2/Phase 3 | |
Completed |
NCT00071266 -
The Dose Response of Niacin ER/Lovastatin on Peak Walking Time (PWT) in Patients With Intermittent Claudication - TROPIC
|
Phase 3 |